Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients

Talha Badar, Mahesh Kumar, Yael Kusne, Terra Lasho, James Foran, Hemant Murthy, Mohamed Kharfan-Dabaja, Timothy Chlon, Naseema Gangat, Hassan Alkhateeb, Abhishek Mangaonkar, Rong He, David Viswanatha, Jennifer Jiang, Yao-Shan Fan, Alejandro Ferrer, Mark Litzow, Aref Al-Kali, Mrinal Patnaik

Blood (2025) 146 (Supplement 1): 1442.

https://doi.org/10.1182/blood-2025-1442

Published: 2025

Journal Articles

Risk-adjusted comparison of survival in chronic myelomonocytic leukemia with and without allogeneic stem cell transplant: Mayo Clinic experience in 775 consecutive patients

Blood (2025) 146 (Supplement 1): 5636.

https://doi.org/10.1182/blood-2025-5636

Published: 2025

Journal Articles

Exposure to agent orange and risk of myelodysplastic syndromes

Mikkael Sekeres, Amy DeZern, Michael Otterstatter, Eric Padron, Tareq Al Baghdadi, James Foran, Rami Komrokji, Gregory Abel, Wael Saber, Steven Gore, Cecilia Lee, Rafael Bejar, Jijun Liu, Joachim Deeg, Seth Sherman, R. Coleman Lindsley, Nancy DiFronzo, Matthew Walter, Nancy Gillis

Blood (2025) 146 (Supplement 1): 5626.

https://doi.org/10.1182/blood-2025-5626

Published: 2025

Journal Articles

Post-transplant cyclophosphamide significantly reduces early non-relapse mortality following allogeneic hematopoietic cell transplantation

Emily Wolf, Megan Melody, Athanasios Tsalatsanis, Suhaib El Khatib, Yenny Moreno Vanegas, Annette Velez-Tirado, Zaid Abdel Rahman, Denise Gococo-Benore, James Foran, Ernesto Ayala, Madiha Iqbal, Ricardo Parrondo, Sikander Ailawadhi, Hemant Murthy, Vivek Roy, Mohamed Kharfan-Dabaja

Blood (2025) 146 (Supplement 1): 7820.

https://doi.org/10.1182/blood-2025-7820

Published: 2025

Journal Articles

Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis

Usman Ilyas, Carolyn Mead-Harvey, Yenny Moreno Vanegas, Muhammad Abdullah Humayun, Kanishka Uttam Chandani, Diana Zamora Quintanilla, Ernesto Ayala, Saurabh Chhabra, James Foran, Talal Hilal, Madiha Iqbal, Mohamed Kharfan-Dabaja, Nandita Khera, Jose Leis, Hemant Murthy, Nathan Punwani, Vivek Roy, Lisa Sproat, Jeanne Palmer

Blood (2025) 146 (Supplement 1): 6016.

https://doi.org/10.1182/blood-2025-6016

Published: 2025

Journal Articles

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in acute myeloid leukemia (AML): An analysis of ECOG-ACRIN clinical trials

Douglas Tremblay, Li Chen, Zhuoxin Sun, Chezi Ganzel, Hugo Fernandez, James Foran, Daniel Arber, Hillard Lazarus, Yanming Zhang, Elisabeth Paietta, John Bennett, Jacob Rowe, Mark Litzow, Martin Tallman, Ehab Atallah, Selina Luger

Blood (2025) 146 (Supplement 1): 871.

https://doi.org/10.1182/blood-2025-871

Published: 2025

Journal Articles

Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles

Shella Saint Fleur-Lominy, Li Chen, Zhuoxin Sun, Francine Garrett-Bakelman, Mihir Shukla, Hugo Fernandez, James Foran, Larry Cripe, Hillard Lazarus, Peter Wiernik, Jacob Rowe, Martin Tallman, Mark Litzow, Yanming Zhang, Selina Luger, Irum Khan

Blood (2025) 146 (Supplement 1): 290.

https://doi.org/10.1182/blood-2025-290

Published: 2025

Journal Articles

The synonymous IDH1 p.Gly105Gly (rs11554137) variant associates with AML post-transplant relapse via aberrant signal transduction pathways

Blood (2025) 146 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2025-1699

Published: 2025

Journal Articles

Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study

Tariq Kewan, Oudai Alkabbani, Rong He, Dragan Jevremovic, Patricia Greipp, Antoine Saliba, Aasiya Matin, Mehrdad Hefazi Torghabeh, Abhishek Mangaonkar, Naseema Gangat, William Hogan, Mrinal Patnaik, Hassan Alkhateeb, Cecilia Arana Yi, James Foran, Mark Litzow, Mithun Shah, Kebede Begna, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 996.

https://doi.org/10.1182/blood-2025-996

Published: 2025

Journal Articles

Insights into clonal and CBC changes at disease evolution among ccus patients

Yazan Jabban, Rong He, Kurt Bessonen, Patricia Greipp, Dragan Jevremovic, David Viswanatha, James Foran, Talha Badar, Cecilia Arana Yi, Yael Kusne, Antoine Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, William Hogan, Abhishek Mangaonkar, Mithun Shah, Hassan Alkhateeb, Mrinal Patnaik, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 5621.

https://doi.org/10.1182/blood-2025-5621

Published: 2025

Journal Articles

Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study

Blood (2025) 146 (Supplement 1): 882.

https://doi.org/10.1182/blood-2025-882

Published: 2025

Journal Articles

Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML

Blood (2025) 146 (Supplement 1): 7045.

https://doi.org/10.1182/blood-2025-7045

Published: 2025

Journal Articles

Survival differences in metropolitan versus nonmetropolitan/rural counties in the US: An analysis according to rural-urban continuum codes (RUCC) in the lymphoma epidemiology of outcomes (LEO) study cohort

Blood (2025) 146 (Supplement 1): 6324.

https://doi.org/10.1182/blood-2025-6324

Published: 2025

Journal Articles

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

Blood (2025) 146 (Supplement 1): 5643.

https://doi.org/10.1182/blood-2025-5643

Published: 2025

Journal Articles

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Steven Tessier, Najla Al Ali, Michael Trinh, Andrew Brunner, Diletta Fontana, Carlo Gambacorti-Passerini, Rocco Piazza, David Sallman, Eric Padron, Zhuoer Xie, James Foran, Cecilia Arana Yi, Hassan Alkhateeb, Mithun Shah, Rami Komrokji, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 3864.

https://doi.org/10.1182/blood-2025-3864

Published: 2025

Journal Articles

Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study

Blood (2025) 146 (Supplement 1): 3845.

https://doi.org/10.1182/blood-2025-3845

Published: 2025

Journal Articles

Integrated prognostic model for TP53‑mutated myeloid neoplasms across all myeloid neoplasm subtypes

Blood (2025) 146 (Supplement 1): 2087.

https://doi.org/10.1182/blood-2025-2087

Published: 2025

Journal Articles

CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients

Blood (2025) 146 (Supplement 1): 1602.

https://doi.org/10.1182/blood-2025-1602

Published: 2025

Journal Articles

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 790.

https://doi.org/10.1182/blood-2025-790

Published: 2025

Journal Articles

Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study

Blood (2025) 146 (Supplement 1): 7370.

https://doi.org/10.1182/blood-2025-7370

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients

Risk-adjusted comparison of survival in chronic myelomonocytic leukemia with and without allogeneic stem cell transplant: Mayo Clinic experience in 775 consecutive patients

Exposure to agent orange and risk of myelodysplastic syndromes

Post-transplant cyclophosphamide significantly reduces early non-relapse mortality following allogeneic hematopoietic cell transplantation

Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in acute myeloid leukemia (AML): An analysis of ECOG-ACRIN clinical trials

Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles

The synonymous IDH1 p.Gly105Gly (rs11554137) variant associates with AML post-transplant relapse via aberrant signal transduction pathways

Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study

Insights into clonal and CBC changes at disease evolution among ccus patients

Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML

Survival differences in metropolitan versus nonmetropolitan/rural counties in the US: An analysis according to rural-urban continuum codes (RUCC) in the lymphoma epidemiology of outcomes (LEO) study cohort

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study

Integrated prognostic model for TP53‑mutated myeloid neoplasms across all myeloid neoplasm subtypes

CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only